{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:06:00Z","timestamp":1784696760718,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016079","name":"Science and Technology Department of Xinjiang Uygur Autonomous Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016079","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This retrospective study aimed to evaluate the efficacy, safety, and prognostic factors of Iodine-125 seed brachytherapy for Retroperitoneal Lymph Node Metastases (RLNM) from a Previously Irradiated Field in Cervical Carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between March 2020 and November 2024, 33 patients (40 lesions) with RLNM from Cervical Carcinoma, who were ineligible for or declined further external beam radiotherapy (EBRT), underwent CT-guided iodine-125 seed brachytherapy at three tertiary hospitals. The follow-up deadline was 28\/02\/2026. The following endpoints were assessed: disease control rate (DCR), local tumor progression-free survival (LTPFS), overall survival (OS), and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median follow-up time was 18.6 months (range, 2.0-38.3 months), and the 3- and 6- month DCR was 90.0% and 77.5%, respectively. The median LTPFS was 9.0 months (IQR, 5.3 - 20.5), and the median OS was 20.0 months (IQR, 8.0 - 25.0). The 6-, 12-, 18- and 24- month survival rates were 81.8%, 60.5%, 50.2%, 28.2%, respectively. Among 8 patients with preoperative pain, the Numerical Rating Scale (NRS) score decreased from 3.50\u00a0\u00b1\u00a01.77 to 1.75\u00a0\u00b1\u00a01.49 one month postoperatively (t=3.564, P\u00a0=\u00a00.009), a statistically significant difference. One patient developed a sigmoid colon fistula 4 months postoperatively. Four patients experienced postoperative low back discomfort with NRS scores of 1-2, which was relieved spontaneously or with oral analgesics. Multivariate analysis using the Cox proportional hazards model showed that a dose to 90% of the gross tumor volume (D90) \u2265 108 Gy was a protective factor for LTPFS, and tumor invasion of the intestinal wall was a risk factor for OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Iodine-125 seed brachytherapy is safe and effective for treating RLNM in Cervical Carcinoma. A D90 \u2265 108 Gy results in better LTPFS. Tumor invasion of the intestinal wall is a risk factor for OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1897353","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:39:17Z","timestamp":1784695157000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors and outcomes of CT-guided Iodine-125 seed brachytherapy for retroperitoneal lymph node metastases from a previously irradiated field in cervical carcinoma: a multicenter retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Shule","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Oncology, Wardne, Hebei General Hospital","place":["Shijiazhuang, China"]},{"name":"Graduate School Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Di","sequence":"additional","affiliation":[{"name":"Department of Oncology, Wardne, Hebei General Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Wardne, Hebei General Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Wardne, Hebei General Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Wardne, Hebei General Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Wardne, Hebei General Hospital","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuande","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Interventional Diagnosis and Treatment, Affiliated Cancer Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Qingdao University Affiliated Hospital Interventional Medicine Center","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wukui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Interventional Diagnosis and Treatment, Affiliated Cancer Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Wardne, Hebei General Hospital","place":["Shijiazhuang, China"]},{"name":"Graduate School Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"13994","DOI":"10.1038\/s41598-022-17733-8","article-title":"Cervical cancer prognosis and related risk factors for patients with cervical cancer: a long-term retrospective cohort study","volume":"12","author":"Li","year":"2022","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02697-2","article-title":"Re-evaluating prognostic factors for cervical cancer with lymph node metastasis: a Japanese multicenter cohort study based on FIGO 2018","volume":"30","author":"Hamada","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ijgo.70366","article-title":"Oncologic outcome and recurrence patterns of clinical stage IB and IIA cervical cancer: A large retrospective analysis of a tertiary reference center","volume":"172","author":"A\u015f\u0131c\u0131o\u011flu","year":"2026","journal-title":"Int J Gynaecol Obstet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.06.207","article-title":"Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence","volume":"61","author":"Singh","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.12.018","article-title":"Post-recurrence survival in patients with cervical cancer","volume":"164","author":"Cibula","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000615","article-title":"Para-aortic lymph node recurrence after curative radiotherapy for cervical cancer","volume":"29","author":"Cho","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn113030-20250428-00166","article-title":"Clinical guidelines of the diagnosis and therapy of recurrent and metastatic uterine cervical cancer[J","volume":"33","year":"2025","journal-title":"Chin J Radiat Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59020192","article-title":"Assessment of salvage surgery in persistent cervical cancer after definitive radio-chemotherapy: A systematic review","volume":"59","author":"Conte","year":"2023","journal-title":"Medicina"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.14093","article-title":"Salvage surgery for patients with residual disease after chemoradiation therapy for locally advanced cervical cancer: A systematic review on indication, complications, and survival","volume":"100","author":"Van Kol","year":"2021","journal-title":"Acta Obstetricia Gynecologica Scandinavica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29080418","article-title":"Re-irradiation for recurrent cervical cancer: A state-of-the-art review","volume":"29","author":"Shen","year":"2022","journal-title":"Curr Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111237","article-title":"Multicenter analysis of MRI-guided, stereotactic body radiotherapy as ablative treatment for lymph nodal metastases of the abdomen and pelvis","volume":"214","author":"von der Gr\u00fcn","year":"2026","journal-title":"Radiother Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-001115","article-title":"Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological Malignancies: a multi-institutional analysis","volume":"30","author":"Onal","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-002466","article-title":"Role of stereotactic body radiotherapy in gynecologic radiation oncology","volume":"32","author":"Shenker","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2024.40681","article-title":"Stereotactic body radiation therapy on abdominal-pelvic lymph node oligometastases: a systematic review on toxicity","volume":"29","author":"Van Werkhoven","year":"2024","journal-title":"Acta Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187390","article-title":"Dosimetric comparison of CT-guided iodine-125 seed stereotactic brachytherapy and stereotactic body radiation therapy in the treatment of NSCLC","volume":"12","author":"Li","year":"2017","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.700710","article-title":"Chinese expert consensus on iodine125 seed implantation for recurrent cervical cancer in 2021","volume":"11","author":"Jiang","year":"2021","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1008-794X.2017.02.010","article-title":"125I seed implantation for the treatment of 10 cases of recurrent retroperitoneal lymph node metastasis after radiotherapy of cervical cancer","volume":"26","author":"Di","year":"2017","journal-title":"J Interventional Radiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.2147","article-title":"Efficacy and safety of 125I seed implantation in the treatment of pelvic recurrent cervical cancer following radiotherapy: A single-arm meta-analysis of chinese patients","volume":"7","author":"Wang","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13014-024-02454-1","article-title":"125I seed brachytherapy for non-central pelvic recurrence of cervical cancer after external beam radiotherapy","volume":"19","author":"Di","year":"2024","journal-title":"Radiat Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S139571","article-title":"CT-guided 125I interstitial brachytherapy for pelvic recurrent cervical carcinoma after radiotherapy","volume":"17","author":"Tong","year":"2017","journal-title":"Onco Targets Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_597_19","article-title":"Feasibility and clinical value of computed tomography-guided125I brachytherapy for pain palliation in patients with retroperitoneal lymph node metastases","volume":"16","author":"Mai","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e9","article-title":"Efficacy and dosimetry analysis of image-guided radioactive 125I seed implantation as salvage treatment for pelvic recurrent cervical cancer after external beam radiotherapy","volume":"30","author":"Qu","year":"2018","journal-title":"J Gynecologic Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-013-0613-3","article-title":"CT-guided radioactive \u00b9\u00b25I seed implantation therapy of symptomatic retroperitoneal lymph node metastases","volume":"37","author":"Wang","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B25","first-page":"363","article-title":"Short- and Long-Term Outcomes of Different Treatment Modalities for Pelvic RecurrentCervical Cancer After Radiotherapy: A Small-Sample Retrospective Study [J]","volume-title":"Chongqing  Med J.","author":"Luo","year":"2026"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.943703","article-title":"Image-guided interstitial brachytherapy for recurrent cervical cancer after radiotherapy: A single institution experience","volume":"12","author":"Ren","year":"2022","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1442-6","article-title":"Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment","volume":"14","author":"Kubota","year":"2019","journal-title":"Radiat Oncol (London England)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897353\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:39:37Z","timestamp":1784695177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897353\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":27,"alternative-id":["10.3389\/fonc.2026.1897353"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1897353","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1897353"}}